Roundup Ruling: Why SCOTUS Didn't End the War on Bayer's Weedkiller

DALLAS, TX – June 26, 2026 – At first glance, the U.S. Supreme Court’s decision in Monsanto Co. v. Durnell looked like a decisive victory for Bayer, the German conglomerate that inherited a mountain of litigation when it acquired Monsanto in 2018. The court ruled that the makers of Roundup cannot be sued under state law for failing to place a cancer warning on the herbicide's label. For a company facing tens of thousands of claims, it was a moment of profound relief. Yet, in the complex world of mass tort litigation, a single court ruling rarely tells the whole story. A closer look reveals that while one major legal avenue has been closed, others remain wide open, signaling a strategic pivot rather than an end to the legal saga.

Plaintiffs' attorneys, representing thousands of cancer victims, are already recalibrating. They argue the court’s decision is a narrow one, surgically removing one type of claim while leaving the core of their case intact. The actionable intelligence for professionals and consumers alike is clear: the financial and reputational fallout for Bayer is not contained, and the fundamental questions about Roundup's safety persist.

A Ruling of Preemption, Not Vindication

The Supreme Court's 7-2 decision, authored by Justice Brett Kavanaugh on June 25, 2026, centered on the legal principle of federal preemption. The court found that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) gives the Environmental Protection Agency (EPA) sole authority over pesticide labeling. Since the EPA has repeatedly determined that a cancer warning is not required for glyphosate-based products like Roundup, the court concluded that state-level lawsuits demanding such a warning are preempted by federal law. This decision directly overturned a $1.25 million verdict awarded to John Durnell, who argued Monsanto should have warned him of the risks that led to his non-Hodgkin's lymphoma.

However, attorneys for the plaintiffs were quick to point out the ruling's limitations. “While we’re disappointed with the Durnell ruling, the language of the decision makes clear that its scope is limited to failure-to-warn claims,” says trial team partner Gibbs Henderson of the Nachawati Law Group. Henderson’s firm represents thousands of claimants. He points to Kavanaugh’s own words in the majority opinion, which explicitly state that Monsanto was relying on the EPA’s specific label determination, and that “non-warning claims were not even at issue in Durnell.”

“In other words, the court’s majority acknowledged that non-warning claims were not even at issue,” Henderson emphasized. This distinction is the critical loophole through which the litigation will now flow. The ruling doesn't absolve the product itself; it only protects the company from liability over the contents of its federally approved label.

The Strategic Pivot to Design Defect

With failure-to-warn claims now largely off the table, the legal battlefield is shifting to a different front: design defect. This legal theory argues that a product is inherently and unreasonably dangerous due to its formulation, regardless of any warnings provided to the consumer. For Roundup, the argument is that its chemical makeup, containing the active ingredient glyphosate, is fundamentally unsafe and caused claimants' cancer.

This is not a novel strategy, but it is now the primary one. “Both our firm and others have taken design defect claims to the jury, and many jurors across the country have concluded, consistent with the applicable standard in most states, that Roundup is unreasonably dangerous because it failed to perform as safely as an ordinary consumer would expect when used as intended,” Henderson stated. “We fully expect to have continued success with this claim in our upcoming Roundup trials.”

This strategy has proven effective before. Prior to the Durnell ruling, juries awarded staggering sums in cases that often combined failure-to-warn and design defect arguments, including a $289 million verdict in 2018 and a $2 billion verdict in 2019 (both later reduced). Bayer has already allocated over $11 billion to settle a majority of the roughly 170,000 claims filed. With approximately 60,000 cases still pending, the focus on design defect ensures the financial pressure on the company will continue.

The Unsettled Science Fueling the Fire

Underpinning the entire legal conflict is a deep and persistent scientific schism. On one side is the EPA, which maintains that glyphosate is “not likely to be carcinogenic to humans” when used as directed. This assessment, which focuses on real-world risk, relies on a vast dataset that includes industry-funded studies.

On the other side is the World Health Organization’s International Agency for Research on Cancer (IARC), which in 2015 classified glyphosate as “probably carcinogenic to humans.” The IARC’s hazard-based assessment, which evaluates whether a substance can cause cancer under any circumstances, relied exclusively on publicly available, peer-reviewed research. This classification was the spark that ignited the explosion of litigation against Monsanto.

This scientific standoff has been complicated by accusations of corporate influence. In a telling development, a scientific journal in December 2025 retracted a 2000 study that had supported glyphosate's safety, citing evidence of undisclosed involvement from Monsanto in its drafting. Furthermore, the 9th U.S. Circuit Court of Appeals has ordered the EPA to revisit and further explain its safety determination for glyphosate, suggesting that even the regulatory foundation Bayer relies on is not as solid as it appears.

A Market Retreat Without a Safety Recall

The hidden cost of this decade-long legal war is already visible on store shelves. In a move to mitigate litigation risk, Bayer announced it would phase out glyphosate-based Roundup products for the U.S. residential lawn and garden market by 2023. The company steadfastly maintains this is a business decision, not an admission of a safety problem. However, the action speaks volumes. It demonstrates that even with regulatory backing and a major Supreme Court victory, the financial and reputational damage from jury verdicts and public perception can force a product out of a market.

For consumers, this means the original formulation of a globally recognized brand is disappearing, replaced by new formulas with different active ingredients. For Bayer, it represents a strategic retreat from one segment of the market to protect the larger, more lucrative agricultural segment. The Durnell ruling may have fortified one of Bayer's defenses, but the company remains embattled on multiple fronts, fighting a war of attrition in courtrooms, laboratories, and the court of public opinion.